SNX-2112 – 5 mg

Brand:
Cayman
CAS:
908112-43-6
Storage:
-20
UN-No:
Non-Hazardous - /

SNX-2112 is a potent inhibitor of heat shock protein 90 (Hsp90) with a Kd value of 30 nM.{37128} In vitro, SNX-2112 induces down-regulation of the client proteins HER2 and Akt. It inhibits proliferation in a panel of cancer cell lines (IC50s = 10-50 nM). SNX-2112 (150 mg/kg) completely inhibits tumor growth in a BT474 breast cancer mouse xenograft model. SNX-2112 is also the active metabolite of prodrug SNX-5542 and preferentially accumulates in tumor tissue of mice treated with a single oral dose of 75 mg/kg SNX-5542. Formulations containing SNX-2112 are under clinical investigation for treatment of refractory solid tumors.{37129}  

 

Out of stock

SKU: 22359 - Category:

Description

A potent Hsp90 inhibitor (Kd = 30 nM); induces down-regulation of client proteins HER2 and Akt in vitro; inhibits proliferation in a panel of cancer cell lines (IC50s = 10-50 nM); inhibits tumor growth in a BT474 breast cancer mouse xenograft model; active metabolite of the prodrug SNX-5542 and preferentially accumulates in tumor tissue of mice treated with a single oral dose of 75 mg/kg SNX-5542


Formal name: 2-[(trans-4-hydroxycyclohexyl)amino]-4-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl]-benzamide

Synonyms:  PF-04928473

Molecular weight: 464.5

CAS: 908112-43-6

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Heat Shock Proteins||Product Type|Biochemicals|Xenobiotic Metabolites||Research Area|Cancer||Research Area|Cell Biology|Cellular Chaperones